DelveInsight's "ROZLYTREK Market Size, Forecast, and Market Insight Report" highlights the details around ROZLYTREK, an ...

As biomarker testing and the demand for tumor-agnostic therapies rise, ROZLYTREK can potentially target a specialized yet valuable market segment. While competition from other TRK inhibitors ...

All the latest breaking news on United States. Browse ibtimes archives of photos, videos and articles on United States.

Pfizer’s ALK inhibitor Xalkori is facing a further challenge from Takeda newcomer Alunbrig, which outperformed it in a phase 3 trial. Takeda has reported updated results from its ALTA-1L trial ...

Pfizer’s Xalkori is already approved to treat patients with ROS1 mutations (alongside its use in ALK+ patients), but Ignyta’s drug looks likely to be superior, thanks in part to its ability to ...

During a Case-Based Roundtable® event, Vamsidhar Velcheti, MD, discussed the TRIDENT-1 trial and practical considerations for ...

Pharmac has today announced their decision to fund six medicines for cancer, including a combination treatment, and one ...

Associate Health Minister with responsibility for Pharmac David Seymour, and Health Minister Simeon Brown welcome Pharmac's decision to fund medicines ...

for a type of blood cancer called acute lymphoblastic leukaemia that has come back after prior treatment crizotinib (branded as Xalkori) for a type of advanced non-small cell lung cancer with an ROS1 ...